Abstract
CT537 - A phase 2, multicenter, randomized, double-blind trial of maintenance therapy with FLT3 inhibitor gilteritinib (ASP2215) in patients with FLT3/ITD AML (GOSSAMER study)
1 product
1 drug
1 indication
1 target
Indication
Acute Myeloid LeukemiaProduct
GilteritinibDrug
Gilteritinib